Meeting
2016 ASCO Annual Meeting
Efficacy and safety of denosumab from a phase III, randomized, active-controlled study compared with zoledronic acid in patients of Asian ancestry with bone metastases from solid tumors.
Authors
Zefei Jiang
The Hospital Affiliated to Military Medical Science, Beijing, China
Zefei Jiang , Zhimin Shao , Qingyuan Zhang , Yang Yao , Jianxing He , Wangjun Liao , Shukui Qin , Ying Cheng , Yanmei Xu , Jie Dong , Li Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
NCT01920568
Citation
J Clin Oncol 34, 2016 (suppl; abstr 10116)
DOI
10.1200/JCO.2016.34.15_suppl.10116
Abstract #
10116
Poster Bd #
104
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Risk factors associated with skeletal-related events following denosumab cessation among patients with bone metastases from solid tumors: A real-world machine learning approach.
First Author: Alison Stopeck
Poster
2014 ASCO Annual Meeting
Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: A noninferiority phase III trial (SAKK 96/12, REDUSE).
First Author: Arnoud J. Templeton
Poster
2013 ASCO Annual Meeting
Denosumab and zoledronic acid treatment in patients with genitourinary cancers and bone metastases.
First Author: Luis Costa
Poster
2013 ASCO Annual Meeting
Evaluating results from the multiple myeloma subset of patients treated with denosumab or zoledronic acid (ZA) in a randomized phase III study.
First Author: Noopur S. Raje